Please login to the form below

Not currently logged in
Email:
Password:

Ponesimod

This page shows the latest Ponesimod news and features for those working in and with pharma, biotech and healthcare.

Novartis gains EU approval for relapsing MS drug Kesimpta

Novartis gains EU approval for relapsing MS drug Kesimpta

Also recently entering the RMS market is Johnson &Johnson’s (J&J) Ponvory (ponesimod), which scored approval in the US in March.

Latest news

  • J&J’s multiple sclerosis therapy Ponvory moves closer to EU approval J&J’s multiple sclerosis therapy Ponvory moves closer to EU approval

    J&J's pharma division Janssen announced today that the  CHMP recommends approval of the marketing authorisation for Ponvory (ponesimod), for the treatment of adult patients with relapsing MS (RMS), with ... Despite continuous innovations in the

  • J&J’s MS drug ponesimod receives approval in the US J&J’s MS drug ponesimod receives approval in the US

    Johnson &Johnson’s (J&J) pharma division Janssen has announced that the US Food and Drug Administration (FDA) has approved its multiple sclerosis (MS) treatment ponesimod, under the brand name Ponvory.

  • J&J aims for US approval of MS drug ponesimod J&J aims for US approval of MS drug ponesimod

    J&J acquired the S1P receptor modulator as part its $30bn takeover of Actelion, with the FDA application based on the head-to-head phase 3 OPTIMUM study comparing ponesimod to ... Data from that trial showed that treatment with ponesimod was associated

  • J&J’s ponesimiod tops Aubagio in head-to-head MS trial J&J’s ponesimiod tops Aubagio in head-to-head MS trial

    Sets up regulatory filings and possible approval next year. Johnson &Johnson’s oral multiple sclerosis (MS) therapy ponesimod outperformed Sanofi blockbuster Aubagio in a phase 3 comparative trial, setting up regulatory ... Ponesimod, a S1P receptor

  • J&J agrees $30bn deal to acquire Actelion J&J agrees $30bn deal to acquire Actelion

    J&J also takes control of Actelion's late-stage pipeline, including multiple sclerosis candidate ponesimod and cadazolid for diarrhoeal disease, and the US group has also taken an option on

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....
Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....